Reported about 22 hours ago
Vertex Pharmaceuticals, which specializes in developing drugs for serious diseases, has seen its stock decline significantly, underperforming both the market and its sector over the past year. Despite better-than-expected financial results, its stock fell sharply after a recent earnings report due to a setback in drug trials. Analysts give the stock a consensus 'Moderate Buy' rating, with 33 analysts divided into strong buy, moderate buy, holds, and one strong sell. The average price target suggests significant upside potential.
Source: YAHOO